Libmeldy (Atidarsagene Autotemcel)

Atidarsagene autotemcel is a lentiviral vector that delivers a functional copy of the ARSA gene into the patient’s own CD34+ hematopoietic stem cells. After ex vivo modification, the cells are reinfused, where they engraft in the bone marrow and continuously produce arylsulfatase A, reducing sulfatide buildup in the nervous system.

The dose of Libmeldy is individualized. The prescribing physician determines the number of autologous CD34+ cells to be collected, transduced and reinfused based on patient‑specific factors such as body weight, disease stage and manufacturing yield. No fixed public dosing regimen is provided.

Safety data for Libmeldy in pregnant or breastfeeding individuals are limited. It is generally recommended to avoid use unless the potential benefit outweighs the potential risk to the fetus or infant, and the decision should be made by a specialist familiar with the therapy.

To request Libmeldy, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and the necessary import documentation.

Unlike supportive care or hematopoietic stem‑cell transplantation, Libmeldy directly addresses the underlying enzyme deficiency by providing a functional ARSA gene. This can result in broader and more sustained neurological benefit, especially when administered early, whereas other options mainly aim to slow progression without correcting the metabolic defect.

Libmeldy is supplied as a refrigerated autologous cell suspension. It must be stored at 2‑8 °C, protected from light, and never frozen or shaken. Handling should follow aseptic techniques and cold‑chain procedures to maintain cell viability until infusion.

Libmeldy is administered intravenously after the patient’s CD34+ stem cells have been harvested, genetically modified ex vivo, and quality‑controlled. The final cell suspension is infused over a defined period under close clinical monitoring, typically in a specialized transplant or gene‑therapy centre.

The most serious risks include graft failure or poor engraftment, insertional oncogenesis that could lead to malignancy, severe opportunistic infections during immune reconstitution, and autoimmune complications. Ongoing monitoring for these events is essential throughout the treatment course and long‑term follow‑up.

Libmeldy is contraindicated in patients with active uncontrolled infections, severe organ dysfunction that precludes stem‑cell transplantation, or those who cannot undergo the required pre‑conditioning regimen. Additionally, individuals with a history of adverse reactions to lentiviral vectors should be evaluated carefully before treatment.